Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRSN Neurosense Therapeutics Ltd

Trading 04-13 11:23:38 EDT

0.7300

+0.0300

+4.29%

High0.7380	Low0.6967	Vol43.96K
Open0.6967	D1 Closing0.7000	Amplitude5.90%
Mkt Cap25.81M	Tradable Cap19.44M	Total Shares35.35M
T/O32.01K	T/O Rate0.17%	Tradable Shares26.63M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRSN","market":"US","secType":"STK","nameCN":"Neurosense Therapeutics Ltd","latestPrice":0.73,"timestamp":1776093476899,"preClose":0.7,"halted":0,"volume":43958,"delay":0,"changeRate":0.0428571428571429,"floatShares":26633400,"shares":35349813,"eps":-0.436593,"marketStatus":"Trading","change":0.03,"latestTime":"04-13 11:23:38 EDT","open":0.6967,"high":0.738,"low":0.6967,"amount":32006.129264320003,"amplitude":0.059,"askPrice":0.73,"askSize":100,"bidPrice":0.6977,"bidSize":143,"shortable":3,"etf":0,"ttmEps":-0.436593,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776110400000},"marketStatusCode":2,"adr":0,"listingDate":1639026000000,"exchange":"NASDAQ","adjPreClose":0.7,"preHourTrading":{"tag":"盘前","latestPrice":0.68,"preClose":0.7,"latestTime":"04:00 EDT","volume":4,"amount":2.72,"timestamp":1776067207853,"change":-0.02,"changeRate":-0.028571,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.6859,"preClose":0.7,"latestTime":"19:55 EDT","volume":10652,"amount":7313.303,"timestamp":1775865359806,"change":-0.0141,"changeRate":-0.020143,"amplitude":0.020143},"volumeRatio":1.027677},"requestUrl":"/m/hq/s/NRSN/tweets","defaultTab":"tweets","newsList":[{"id":"2625674919","title":"NeuroSense wins Brazil patent for PrimeC composition, extending protection to 2042","url":"https://stock-news.laohu8.com/highlight/detail?id=2625674919","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625674919?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:20","pubTimestamp":1775481625,"startTime":"0","endTime":"0","summary":"Patent protection in Brazil runs through October 2042.Grant follows prior patents in U.S.  and Australia .Coverage supports PrimeC development in ALS, including planned Phase 3 PARAGON trial.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDLR8q14:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624668120","title":"NeuroSense gets Nasdaq notice for breaching $1 minimum bid price requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624668120","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624668120?lang=en_us&edition=fundamental","pubTime":"2026-04-03 22:03","pubTimestamp":1775224989,"startTime":"0","endTime":"0","summary":"NeuroSense received Nasdaq notices for failing to meet continued listing standards on minimum bid price, Nasdaq rule 5550, plus market value of listed securities, Nasdaq rule 5550.Non-compliance followed ordinary shares closing below $1 for 30 consecutive business days from Feb. 18, 2026 to March 31, 2026.Market value of listed securities also stayed below $35 million for 30 consecutive business days over same period.Nasdaq set Sept. 29, 2026 deadline to regain compliance, requiring at least 10 consecutive business days at or above $1 closing bid.Market value threshold requires 10 consecutive business days at or above $35 million to cure deficiency, subject to Nasdaq discretion.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL76W24:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624501982","title":"Neurosense Therapeutics Ltd. (NRSN) Receives a Buy from Roth MKM","url":"https://stock-news.laohu8.com/highlight/detail?id=2624501982","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624501982?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:46","pubTimestamp":1775134019,"startTime":"0","endTime":"0","summary":"In a report released today, Boobalan Pachaiyappan from Roth MKM maintained a Buy rating on Neurosense Therapeutics Ltd., with a price target of $3....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-receives-a-buy-from-roth-mkm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurosense-therapeutics-ltd-nrsn-receives-a-buy-from-roth-mkm-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624541338","title":"NeuroSense files Form 3 as CFO Or Eisenberg reports beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2624541338","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624541338?lang=en_us&edition=fundamental","pubTime":"2026-04-02 04:25","pubTimestamp":1775075146,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics CFO Or Eisenberg filed initial Form 3 disclosing direct ownership of 1 million ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 01, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL2RRdsM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555048","title":"NeuroSense FY25 net loss widens 9% to USD 11.1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555048","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555048?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:53","pubTimestamp":1774993995,"startTime":"0","endTime":"0","summary":"NeuroSense reported a net loss of USD 11 million.Research and development expense climbed 8.8% to USD 6.2 million, due mainly to higher share-based pay and increased salaries and social benefits.FDA cleared initiation of PARAGON Phase 3 ALS trial, following Phase 2b PARADIGM data showing a 65% reduction in risk of death with more than 14-month median survival benefit.NeuroSense targets a pre-NDS meeting with Health Canada in May 2026, with a potential Canada filing subject to regulatory feedback.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL2vtNmj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624530634","title":"NeuroSense Therapeutics director Revital Mandil-Levin files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2624530634","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624530634?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:28","pubTimestamp":1774988932,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics director Revital Mandil-Levin filed an initial Form 3 showing direct ownership of 189,370 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL8Bwrjt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623457582","title":"Israel's NeuroSense Therapeutics 2025 net loss widens as expenses rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2623457582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623457582?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:31","pubTimestamp":1774963896,"startTime":"0","endTime":"0","summary":"Israel's NeuroSense Therapeutics 2025 net loss widens as expenses riseOverviewIsrael biotechnology firm's 2025 net loss widened, with increased R&D and admin expensesCompany advanced PrimeC into late-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL1N40J0N7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582379","title":"BRIEF-NeuroSense Therapeutics FY EPS USD -0.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582379","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623582379?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:20","pubTimestamp":1774963245,"startTime":"0","endTime":"0","summary":"BRIEF-NeuroSense Therapeutics FY EPS USD -0.44\n\n\nMar 31 (Reuters) - NeuroSense Therapeutics FY operating income USD -11.085 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXDE3163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623858281","title":"Neurosense Therapeutics FY Operating Income USD -11.085 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623858281","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623858281?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:20","pubTimestamp":1774963201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXDE3163:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623582813","title":"Neurosense Therapeutics FY EPS USD -0.44","url":"https://stock-news.laohu8.com/highlight/detail?id=2623582813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623582813?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:20","pubTimestamp":1774963201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLXDE3163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623258236","title":"Press Release: NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2623258236","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623258236?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:20","pubTimestamp":1774963200,"startTime":"0","endTime":"0","summary":"-- 2025 marked transition of PrimeC into a late-stage clinical asset with. -- Statistically significant survival benefit demonstrated, including 65%. reduction in risk of death and >14-month median survival advantage. -- Results published in JAMA Neurology, providing high-level peer-reviewed. CAMBRIDGE, Mass., March 31, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  , a late-stage clinical biotechnology company developing treatments for severe neurodegenerative diseases, today reported its financial results for the year ended December 31, 2025 and provided a business update.\"2025 was a transformational year for NeuroSense, as we advanced PrimeC from a successful Phase 2b program into a late-stage clinical asset with a clear regulatory path forward,\" said Alon Ben-Noon, Chief Executive Officer of NeuroSense. \"As we entered 2026, we further strengthened our clinical and scientific foundation with statistically significant survival data and publication of our results in JAMA Neurology","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","LENZ","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324643","title":"NeuroSense files Form 3 for CTO Niva Russek-Blum initial beneficial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324643","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324643?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:38","pubTimestamp":1774906707,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics CTO Niva Russek-Blum reported direct holdings of 258,000 ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDLc9dg9M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623834882","title":"NeuroSense CEO Alon Ben-Noon files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2623834882","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623834882?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:52","pubTimestamp":1774875168,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics CEO Alon Ben-Noon filed an initial Form 3 disclosing direct ownership of about 4.2 million ordinary shares as of March 18, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 30, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1P6QTQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621067279","title":"NeuroSense to report clinical and biomarker results from Alzheimer’s study in coming weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067279","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067279?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:03","pubTimestamp":1774357439,"startTime":"0","endTime":"0","summary":"NeuroSense rescheduled its pre-New Drug Submission meeting with Health Canada to May 2026 to include additional clinical, biomarker, and survival analyses for PrimeC.Clinical and biomarker results from NeuroSense’s Alzheimer’s study have not yet been presented and are expected in the coming weeks.The company cited prior data showing a 65% reduction in risk of death associated with PrimeC.NeuroSense said the FDA has cleared initiation of the Phase 3 PARAGON trial in ALS.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL8zlKf9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620208261","title":"NeuroSense Therapeutics Director Cary J. Claiborne Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620208261","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620208261?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862603,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics director Cary Claiborne filed an initial statement of beneficial ownership. Claiborne reported directly owning 48,000 ordinary shares. He also reported directly owning 60,000 ordinary shares and 99,898 ordinary shares. Claiborne reported options to purchase 72,000 ordinary shares at an exercise price of USD 1.43.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL4mh6sd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620261222","title":"NeuroSense Therapeutics Ltd. Director Roy Golan Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261222","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261222?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862587,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics reported an initial statement of beneficial ownership for director Roy Golan. Golan reported direct beneficial ownership of 24,000 ordinary shares. Golan also reported direct beneficial ownership of 60,000 ordinary shares. Golan also reported direct beneficial ownership of 76,844 ordinary shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6Gn9Mg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620261270","title":"NeuroSense Therapeutics Ltd. Director Mark Leuchtenberger Files Initial Beneficial Ownership Statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2620261270","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620261270?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862576,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics reported an initial statement of beneficial ownership by director Mark Leuchtenberger. Mark Leuchtenberger reported direct beneficial ownership of 128,000 ordinary shares. He also reported direct beneficial ownership of 75,000 ordinary shares. He also reported direct beneficial ownership of 122,951 ordinary shares. Mark Leuchtenberger reported fully vested options to purchase 192,000 ordinary shares at a conversion or exercise price of USD 4.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL9zB1kW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRSN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620726127","title":"NeuroSense Therapeutics Ltd. files Form 3 initial beneficial ownership statement for General Manager Hagit Binder","url":"https://stock-news.laohu8.com/highlight/detail?id=2620726127","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620726127?lang=en_us&edition=fundamental","pubTime":"2026-03-19 03:36","pubTimestamp":1773862566,"startTime":"0","endTime":"0","summary":"NeuroSense Therapeutics reported an initial statement of beneficial ownership by Hagit Binder, its General Manager. Binder reported direct ownership of 12,836 ordinary shares. She also reported direct ownership of 32,000 ordinary shares. Binder reported direct ownership of 266,970 ordinary shares. She reported options to purchase 36,000 ordinary shares with an exercise price of USD 2.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 18, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL2pP3lx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620253314","title":"NeuroSense to Present PrimeC Phase 2b PARADIGM Data at AD/PD 2026 Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2620253314","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620253314?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:04","pubTimestamp":1773835472,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on March 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1fLsDM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRSN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620470649","title":"Health Rounds: Blood test improves detection of endometriosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2620470649","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620470649?lang=en_us&edition=fundamental","pubTime":"2026-03-18 03:31","pubTimestamp":1773775865,"startTime":"0","endTime":"0","summary":"Health Rounds: Blood test improves detection of endometriosis Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us?Forward this newsletter to them. They can also subscribe hereBy Nancy LapidMarch 17  - Hello Health Rounds readers!","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL1N4050X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS","BK4588","BK4583","BK4585","LU2087621335.USD","BK4007","BK4139","NRSN","LU1839511570.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurosense-tx.com","stockEarnings":[{"period":"1week","weight":-0.1566},{"period":"1month","weight":-0.2009},{"period":"3month","weight":-0.3458},{"period":"6month","weight":-0.4118},{"period":"1year","weight":-0.292},{"period":"ytd","weight":-0.0897}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.157004},{"month":2,"riseRate":0.6,"avgChangeRate":0.184296},{"month":3,"riseRate":0.4,"avgChangeRate":0.030043},{"month":4,"riseRate":0.4,"avgChangeRate":-0.135924},{"month":5,"riseRate":0.25,"avgChangeRate":-0.004252},{"month":6,"riseRate":0.75,"avgChangeRate":0.40415},{"month":7,"riseRate":0,"avgChangeRate":-0.235872},{"month":8,"riseRate":0.5,"avgChangeRate":-0.118473},{"month":9,"riseRate":0.5,"avgChangeRate":0.06987},{"month":10,"riseRate":0,"avgChangeRate":-0.14429},{"month":11,"riseRate":0.75,"avgChangeRate":0.430569},{"month":12,"riseRate":0.25,"avgChangeRate":-0.202897}],"exchange":"NASDAQ","name":"Neurosense Therapeutics Ltd","nameEN":"Neurosense Therapeutics Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neurosense Therapeutics Ltd,NRSN,Neurosense Therapeutics Ltd股票,Neurosense Therapeutics Ltd股票老虎,Neurosense Therapeutics Ltd股票老虎国际,Neurosense Therapeutics Ltd行情,Neurosense Therapeutics Ltd股票行情,Neurosense Therapeutics Ltd股价,Neurosense Therapeutics Ltd股市,Neurosense Therapeutics Ltd股票价格,Neurosense Therapeutics Ltd股票交易,Neurosense Therapeutics Ltd股票购买,Neurosense Therapeutics Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neurosense Therapeutics Ltd(NRSN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neurosense Therapeutics Ltd(NRSN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction